Royal Marsden Reports on its Participation in the Significant Checkmate 067 Trial: Survival now Extended for Advanced Melanoma Patients

Royal Marsden Reports on its Participation in the Significant Checkmate 067 Trial: Survival now Extended for Advanced Melanoma Patients

A new treatment based on combining two drugs—nivolumab and ipilimumab—may represent a milestone in how we treat skin cancer patients. More than half of these patients can now survive the condition (considered untreatable just a decade ago) thanks to a study led by the...

Pin It on Pinterest